Lactoferrin is a prominent component of neutrophil secondary granules, and its blood concentration is increased in certain inflammatory diseases. In contrast to the well-described biochemical characterization of lactoferrin as an iron-binding protein, -tS physiologic role in the regulation of inflammation and other host defense mechanisms is unclear. In this report, we provide evidence that lactoferrin has a potent heparinneutralizing activity during thrombin inhibition by the serine proteinase inhibitors (serpins) antithrombin and heparin cofactor II. Activated neutrophil supernatant, which contains lactoferrin and other heparin-binding proteins, could neutralize the heparin-dependent antithrombin-thrombin inhibition reaction. The addition of lactoferrin to plasma corrected LOOD COAGULATION is a host defense system that maintains the integrity of the circulatory system.',' In this process, thrombin serves as a critical factor by activating platelets, activating factors V and VIII, and clotting fibrinogen. After its formation, thrombin is regulated by various anticoagulant pathways."' One pathway is through thrombin inhibition by the plasma serine proteinase inhibitors (serpins) antithrombin and heparin cofactor 11. The thrombin-inhibiting activity of both of these serpins is greatly accelerated in the presence of glycosaminoglycans such as heparin.'.'' In homeostasis, the coagulation process is under tight control by these and other mechanisms. However, certain pathologic conditions, such as septicemia, can shift this balance to the hypercoagulable state partly as a result of the failure of these natural anticoagulant mechanisms. The resulting outcome of such septicemia could be disseminated intravascular coagulation (DIC).'L"4 DIC is a clinical syndrome characterized by uncontrolled thrombin generation in the systemic circulation. The clinical management of DIC has not been well described due to the complexity of its pathogenesis. Understanding this mechanism is critical for the successful treatment of DIC. The current study suggests that one factor that may contribute to the development of septic DIC is lactoferrin liberated from neutrophils in response to bacterial lipopolysaccharide (LPS) and other inflammatory stimulation.
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Lactoferrin is an iron-binding protein closely related in structure to the serum iron-transporting protein, transferrin. The amino acid sequence identity between these proteins is more than %%. I4 Lactoferrin is a single polypeptide chain of 692 residues containing an internal repeat, with the aminoterminal half about 40% identical with the carboxyl-terminal half.I5.l6 Each half of the lactoferrin molecule has a single iron-binding site with a dissociation constant (kd) of approximately lo-'' morn. Human lactoferrin is found in milk, tears, and saliva, and it is also a prominent component of secondary granules of neutrophil^.".'^ Lactoferrin in plasma is originally derived from neutrophils.17 A number of studies have demonstrated that in certain pathologic circumstances, such as severe infection or autoimmune disease, the concentration of plasma lactoferrin can increase twofold to threeIn vitro experiments with isolated neutrophils have also shown that a significant amount of lactoferrin is released from neutrophils in response to LPS and tumor necrosis the heparin-induced prolongation of blood plasma coagulation as measured by the activated partial thromboplastin time ( a m ) . Treatment of whole blood with specific inflammatory mediators, fMLP, lipopolysaccharide (LPS), and tumor necrosis factor-a (TNF-(U) increased the concentration of both plasma lactoferrin and platelet factor 4 while inhibiting the blood anticoagulant activity of heparin as measured by the aP7T. These results suggest that the prothrombotic sequelae of some inflammatory processes may be partly due to various agonists that release neutrophil lactoferrin, which can then neutralize glycosaminoglycan-dependent serpinthrombin inhibition reactions. 0 1995 by The American Society of Hematology.
factor-a (TNF-a)."." However, the physiologic role of plasma lactoferrin during inflammatory processes remains undefined.
Lactoferrin interacts with heparin-Sepharose, and its heparin-binding properties have been partially ~haracterized.'~.'~ Inspection of the primary structure of l a~t o f e r r i n~~.~~ shows that the N-terminus has consensus sequences (BBXB or BXXBBXB, where B is a basic residue and X is any residue)
found in many other glycosaminoglycan-binding protein^.'^ The three-dimensional structure of lactoferrin shows that an a-helical region in the N-terminus forms a positively charged surface that could bind glycosaminoglycans.2**'' Recently, Wu et a129a and Mann et a13' have shown that the glycosaminoglycan-binding site of lactoferrin is localized to the Nterminus of the protein.
The present study examines the role of glycosaminoglycan neutralization by neutrophil-derived lactoferrin in the regulation of blood coagulation. The results suggest that neutrophil lactoferrin is an effective inhibitor of the anticoagulant activity of heparin, and it may be involved in the development of thrombotic complications associated with inflammatory diseases.
grade purity available. Ficoll-Hypaque Monopoly medium, collagen, and polyclonal antibody against human lactofenin conjugated with alkaline phosphatase were obtained from ICN Biochemicals (Costa Mesa, CA); TNF-a, phorbol 12-myristate-l3-acetate (PMA), N-tosyl-phenylalanine chloromethyl ketone (TPCK), and purified human neutrophil elastase were from CalBiochem (San Diego, CA); transforming growth factor-p (TGF-P) was obtained from R & D Systems Inc (Minneapolis, MN); platelet factor 4 (40 kD) and a polyclonal antibody against platelet factor 4 were obtained from American Diagnostics Inc (Greenwich, CT); polyclonal antibody against human neutrophil elastase was from Biodesign (Kennebunk, ME); Polybrene was from Aldrich Chemical CO (Milwaukee, WI); Ne-p-tosylGly-Pro-Arg-p-nitroanilide was from Boehringer-Mannheim (Indianapolis, IN); aPTT reagents were obtained from Pacific Hemostasis (Ventura, CA); and heparin, with an average molecular weight of 15 kD, was provided from Diosynth (Oss, The Netherlands). Human a-thrombin, antithrombin, and heparin cofactor I1 were purified as described pre~iously.".~'
Pur$cation ofluctoferrin. Human milk lactoferrin was purified from fresh mature milk as described by Blackberg and Hernell." For preparation of human neutrophil lactoferrin, 150 mL of blood was drawn from a healthy volunteer with EDTA as an anticoagulant. Neutrophils were isolated using the modified Ficoll-Hypaque gradient as described by Kalmar et al. 33 The granulocyte fraction obtained was composed of greater than 95% polymorphonuclear leukocytes, and it exhibited more than 99% cell viability as determined by trypan blue exclusion. After washing twice with Hanks' Balanced Salt Solution (HBSS) without Ca++ and Mg++, the neutrophils were suspended in HBSS at 5 X 10' cells per milliliter and treated with 100 ng/mL PMA for 30 minutes at room temperature. After centrifugation at 2,000 rpm for 5 minutes, the supernatant was collected and stored at -20°C for further use. Neutrophil supernatants obtained from 10 normal donors were loaded onto a heparin-Sepharose column (2 cm X 1 5 cm). After initial washing with 20 mmol/L HEPES containing 200 m m o m NaCI, pH 7.4, bound proteins were eluted by NaCl gradient (200 to 800 mmol/L). The protein in each fraction was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and by immunoblot analysis.
Neutrophil lactoferrin was eluted from heparin-Sepharose at the same NaCl concentration (0.6 m o m ) a s that of milk lactofenin. We purified approximately 50 pg lactofenin from neutrophils obtained from I L of blood (10 donors). The purity of both milk and neutrophil lactofenin was evaluated using a 10% acrylamide gel with Coomassie Brilliant blue (R-250) staining. A single protein band at 80 kD was observed in both preparations. Immunoblot analysis of both milk-and neutrophil-purified lactofenin with a polyclonal antibody against human lactofenin demonstrated strong immunoreactivity with the same 80-kD band. Purified iron-saturated human lactoferrin was obtained from Sigma and contained greater than 0.15% (wt/ wt) of iron according to the manufacturer's specifications. Iron-free lactofenin was prepared from purified milk lactoferrin as described Thrombin inhibition assay. The assay was performed in 96-well U-bottom microplates (Becton Dickinson, Oxnard, CA) in 100 p L of 0.15 mmol/L NaCI, 0.02 molL HEPES, I mg/mL polyethylene glycol (Mr = 8,000), and 1 mg/mL bovine serum albumin (BSA), pH 7.4. Inhibition reaction mixtures contained 0.1 pg/mL heparin, 50 nmol/L serpin, and various concentrations of lactofenin or other heparin-neutralizing molecules. The reaction was initiated by adding thrombin (5 nmolL) to the microplate well. After an incubation of 30 to 40 seconds, 50 pL of a solution containing 0.2 mmol/L tosylGly-Pro-Arg-p-nitroanilide and 1 .S mg/mL Polybrene was added. Residual thrombin activity was determined by measuring the hydrolysis of the chromogenic substrate in a Molecular Devices (Menlo Park, CA) Vmax kinetic microplate reader. All thrombin inhibition assays were performed at least three times, and mean values of heparin neutralization and standard deviation were determined. Percentage of heparin neutralization is expressed by plotting extent of neutralization of anticoagulant activity against the molar ratio of neutralizing proteinheparin. Heparin neutralization percentage was calculated as follows: heparin neutralization % = [(B -A)/(C -A)J X 100%; where A is the thrombin residual activity obtained in the presence of serpin and heparin; B is the activity obtained in the presence of serpin, heparin, and lactoferrin or other indicated molecules; and C is the activity obtained in the presence of serpin only. Control experiments verified that lactoferrin did not affect ( I ) the activity of thrombin alone, (2) the activity of thrombin in the presence of heparin, or (3) the thrombin inhibition by the serpins in the absence of heparin.
Prepurution of neutrophil-releasing products. Human neutrophils were isolated from venous blood (anticoagulated with EDTA) by centrifugation on Ficoll-Hypaque gradient as described above. The isolated neutrophils were then washed twice with HBSS and suspended in the same solution at a density of 5 X 10' to 10 X 10" cells per milliliter. A 300-pL cell suspension was incubated with various agonists at the indicated concentrations for 30 minutes at 37°C. Incubation was terminated by centrifugation at 2,000 rpm for 5 minutes. The cell-free supernatants were collected and stored at -20°C until assayed.
Enzyme-linked immunosorbent ussuy (ELISA). The concentration of lactoferrin in both plasma and neutrophil supernatants was determined by a double-sandwich ELISA. Briefly, microplate wells were coated with 100 pL of rabbit polyclonal antibody against human purified lactoferrin (Cappel-Organon Teknika Corp, Durham, NC) at a 1 500 dilution at 4°C overnight. The plate was then washed twice with phosphate-buffered saline (PBS) containing 0.05% Tween 20 and 0.5 m o m NaCI, pH 7.5 (washing buffer). After blocking with 1% BSA in PBS for 2 hours, a neutrophil supernatant dilution of 1:200 or a plasma dilution of I :20 in blocking solution containing 0.05% Tween 20 (incubation buffer) was added to the wells in 100-pL volume. After incubation for 2 hours at room temperature, the plate was washed twice with washing buffer. Rabbit anti-human lactoferrin antibody conjugated with alkaline phosphatase at a dilution of 1:5,000 was then added for 1 hour. Finally, the plate was washed four times with washing buffer, and 1 0 0 pL substrate containing I mg/mL p-nitrophenyl-phosphate in 10 mmol/L diethanolamine, 0.5 mmol/L MgCI,, pH 9.5, was added. Substrate hydrolysis was measured kinetically in the microplate reader at 405 nmol/ L. Alkaline phosphatase activity in each well was determined as millioptical density per minute.
The concentration of elastase in activated neutrophil supernatants was measured by a direct ELISA. Microplate wells were coated with the various neutrophil supernatants in PBS at 4°C overnight. After treatment with the washing buffer, the wells were blocked with 2% BSAPBS for 2 hours at 37°C and then incubated with 100 pL rabbit polyclonal antibody against human neutrophil elastase ( I :S00 dilution) in the incubation buffer for 3 hours at 37°C. After washing, a goat anti-rabbit IgG antibody conjugated with alkaline phosphatase (1:SOO dilution) was added for 2 hours at 37°C. Finally, the plate was washed four times with the washing buffer, and 100 &substrate containing 1 mg/mL p-nitrophenyl-phosphate in 10 mmol/L diethanolamine, 0.5 mmol/L MgCI2, pH 9.5, was added. Substrate hydrolysis was measured as described above.
The concentration of platelet factor 4 in the plasma after treatment of whole blood with various inflammatory mediators was determined by a competitive ELISA. Microplate wells were coated with 100 p L of purified platelet factor 4 at 0.5 pg/mL in PBS at 4°C overnight. The plate was then washed twice with PBS and blocked with 2%
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BSA for 2 hours at 37°C. After another washing, a 100-pL incubation solution containing a constant concentration of platelet factor 4 antibody (2 pg/mL) and a diluted plasma sample (from 1:lO to 1:80 dilution) was added and incubated at 37°C for 4 hours. The plate was then washed with washing buffer. A goat anti-rabbit IgG antibody conjugated with alkaline phosphatase at a dilution of 1500 in the incubation solution was then added for 2 hours at 37°C. Alkaline phosphatase activity was measured as described above.
For each ELISA plate, a standard curve was obtained by plotting the activity against concentration of purified protein used in each assay. Each sample was analyzed in duplicate by ELISA, and the average was calculated. The mean values of three separate experiments with standard deviation were reported.
uP7T assays. Coagulation assays were performed in the mi- 
100
sodium citrate, and 2 mL aliquots were mixed with various challengers at the indicated concentrations. The samples were incubated at 37°C in a tissue culture incubator with 5% CO,. At a specific time, the incubation was terminated by centrifugation at 2,000 rpm for 10 minutes at 4°C. The plasma supernatant was collected and centrifuged again at 10, OOO rpm for 5 minutes to remove contaminated platelets. Plasma samples thus obtained were used for both ELISA and aP7T assays. For all the assays used in these studies, mean values and standard deviations (SD) were determined using Cricket Graph version I n on an Apple Macintosh IISi computer (Macintosh, Cupertino, CA).
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RESULTS
The heparin neutralization activity of lactofenin in the antithrombin-thrombin inhibition reaction was compared with platelet factor 4, transferrin, and protamine sulfate. Various forms of lactofenin, including milk lactoferrin, neutro-
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phil lactoferrin, apolactofenin, and hololactoferrin, were also compared for this activity. Heparin neutralization activity of For personal use only. on October 27, 2017. by guest www.bloodjournal.org From activity. Interestingly, neither transferrin nor lysozyme (data not shown) had any heparin neutralization activity. Furthermore, similar results were obtained for heparin neutralization with the various forms of lactoferrin in the thrombin-heparin cofactor I1 inhibition reaction (Fig 2) .
The ability of the products released by activated neutrophils to inhibit the heparin-catalyzed antithrombin-thrombin inhibition reaction was examined (Fig 3) . The supernatants of neutrophils after challenge with fMLP, TN€-a, leukotriene B4 (LTB,), LPS, and interleukin-8 (IL-8) significantly neutralized the heparin activity in the thrombin-antithrombin reaction (Fig 3A) . In contrast, treatment of neutrophils with the chemoattractant TGF-,O did not have any effect compared with untreated neutrophils. Additionally, preincubation of the neutrophil supernatants with a polyclonal antibody against lactoferrin partly reduced the antiheparin activity of neutrophil supernatants examined (Fig 3A) . Normal rabbit IgG, included as a control, did not alter the heparin-neutralizing activities of any of the neutrophil supernatants examined (data not shown).
The concentrations of both lactoferrin and the serine proteinase elastase in neutrophil supernatants were quantitated by ELISA. As shown in Fig 3B, fMLP, TNF-a, LTB4 , LPS, and IL-8 mediated significant release of lactoferrin from neutrophils. The amount of lactoferrin found in these neutrophil supernatants was correlated with the specific heparin neutralization activity (Fig 3A) . Lactoferrin was also released from neutrophils in a dose-dependent manner in response to those agonists (data not shown). The release of low levels of lactoferrin from unstimulated neutrophils is probably due to a trace amount of endotoxin contamination in the in vitro system.*' The concentration of elastase in these neutrophil supernatants was also increased significantly after the treatment with tMLP, TNF-a, LTB4, LPS, and IL-8 (Fig 3C) . However, control experiments showed that none of the neutrophil Supernatants altered thrombin chromogenic substrate activity with or without heparin and that thrombin inhibition by antithrombin was not altered in the presence of either aprotinin and/or TPCK in the reaction (data not shown).
The ability of lactoferrin to neutralize heparin in the complex system of blood plasma coagulation was investigated. Prolongation of the aPTT in heparinized plasma was expressed as the ratio of the aPTT in the presence of heparin to the apTT in the absence of heparin (RCT). Addition of purified lactoferrin to plasma did not change the aPTT in the absence of heparin (data not shown). In heparinized plasma, the RCT was reduced by addition of lactoferrin in a dose-responsive manner (Fig 4) .
The concentration of plasma lactoferrin was also deter- For mined by ELISA after incubation of whole blood with LPS. As shown in Fig 5, the plasma lactoferrin concentration increased in response to LPS treatment in a time-and dosedependent manner. Prolongation of the aPTT by adding heparin to plasma was reduced in LPS-treated blood.
The plasma concentration of both lactoferrin and platelet factor 4 after treatment of whole blood with the various agonists was then quantitated by ELISA (Fig 6) . Treatment of blood with fMLP, LPS, and TNF-a resulted in a significant increase in both lactoferrin and platelet factor 4 levels, while other neutrophil agonists, such as IL-8 and LTB,, did not increase plasma levels of either protein. We then determined the RCT of plasma obtained from these treated blood samples. A reduction of RCT was observed for blood treated with LPS, fMLP, and TNF-a (Fig 6) .
DISCUSSION
It is now well established that glycosaminoglycans such as heparin and heparan sulfate catalyze certain serpin-proteinase inhibition reactions like antithrombin-thrombin, antithrombin-factor Xa, and heparin cofactor 11-thrombin. These inhibition reactions are critical for the control of the hemostatic response.1o336 As there is little heparin-like activity in circulating blood in vivo, the participation of exposed glycosaminoglycan chains at the site of injured tissue is considered critical for the normal function of serpins such as antithrombin and heparin cofactor II.'",364' In some pathologic conditions such as infection, the thrombotic coagulopathy may occur partly as a result of the downregulation of anticoagulation. For instance, elastase released from stimulated neutrophils can contribute to the procoagulant response by directly inactivating ~e r p i n s . 4~~~~
Additionally, platelet factor 4 and other cationic proteins released from platelets and neutrophils neutralize glycosaminoglycans to attenuate glycosaminoglycan-catalyzed serpin inhibition reaction^.^^.^^ In the present study, we demonstrated that neutrophil lactoferrin is another protein that is quite effective in neutralizing heparin-dependent serpin-thrombin inhibition reactions and in blocking the anticoagulant activity of heparin in plasma.
Neutrophil-derived lactoferrin had the same heparin-neutralizing activity in vitro as both platelet factor 4 and lactoferrin purified from milk. We also found that both apo-and holo-lactoferrin had similar heparin neutralization activities, implying that the heparin-binding domain of lactoferrin is not affected by the iron-binding status of the protein. The observed minor differences in heparin neutralization are likely due to the conformational orientation of the protein after iron binding, as demonstrated p r e v i~u s l y . *~*~~"~ In contrast to histidine-rich glycoprotein, which requires divalent cation binding for heparin-neutralizing a c t i~i t y ,~" .~~ the addition of EDTA to lactoferrin did not affect its heparin binding. Despite the fact that lactoferrin belongs to the transferrin family of iron-binding proteins and these proteins share a sequence homology of greater than 55%, transferrin exhibited no heparin-binding properties. This unique heparinbinding function of lactoferrin suggests that, after release from neutrophils, it might play another very important role in regulating inflammation and coagulation. We examined the release of lactofenin from neutrophils by various inflammatory mediators. It has been reported that LPS can stimulate the release of lactoferrin from neutrophils and that this is enhanced by TNF-a, which presumably would be secreted by monocytes.*' Our results show that fMLP, LPS, LTB4, IL-8, and TNF-a could liberate significant amounts of lactofemn from neutrophils, whereas the neutrophil chemoattractant TGF-p did not have any effect. These activated neutrophil supernatants neutralized the heparin-catalyzed antithrombin-thrombin inhibition reaction, and this is partly due to the presence of lactoferrin. It is also likely that neutrophil elastase and other neutrophil cationic WU, LUNDBLAD, AND CHURCH proteins are involved in heparin neutralization in these cific neutrophil-released inflammation product, can directly contribute to the regulation of blood anticoagulation.
To further examine the contribution of lactoferrin in the regulation of blood coagulation, we measured the ability of lactofemn in a plasmahlood-based system to neutralize heparin. The heparin-induced prolongation of the aPTT was shortened by lactofemn in a dose-dependent manner. We also examined the effect of heparin on the aFTT of plasma obtained from whole blood after treatment with LPS and compared that with the concentration of plasma lactofenin. Pretreatment of whole blood with LPS showed time-and dose-dependent heparin-neutralizing activities in heparinized plasma when monitored by the aFTT. There was a correlation between the lactoferrin level in plasma and the reduction in the aPlT of heparinized plasma. However, the concentration of platelet factor 4 in plasma was also increased after treatment of whole blood with various inflammatory mediators. In contrast to our results with isolated neutrophils, incubation of blood with LTB, or IL-8 does not result in elevation of either plasma lactofemn or platelet factor 4. It is conceivable that in this complex system either LTB4 and IL-8 are neutralized by other proteins before their interaction with neutrophils or their activity can only be expressed in close proximity to their target cell. These results indicate that lactoferrin and other cationic proteins like platelet factor 4 can collectively neutralize the anticoagulant activity of heparin in plasma.
A pathologic role of bacterial LPS in the development of septic DIC has been demonstrated in animal The contribution of leukocytes in DIC pathogenesis has also been established in animal studies where DIC did not occur in animals rendered leukopenic." However, the exact rnechanism by which LPS mediates this hypercoagulable response with leukocytes is not fully known. Our results provide evidence that lactofemn released from activated neutrophils may partly contribute to the development of septic DIC by inhibiting glycosaminoglycan-dependent serpins. This hypothesis is supported by the report that a patient with a deficiency in neutrophil lactoferrin had a severe bleeding problem after surgery.54 Failure of adequate thrombus formation in this patient may be related to an absence of lactoferrin, which could be otherwise localized at the site of surgical inflammation.
In summary, we conceive of an in vivo scenario where, at certain inflammatory lesions, a large amount of neutrophil lactoferrin could accumulate, which impedes glycosaminoglycan-dependent serpin activity. Other cationic protein-(ase)s released from platelets (platelet factor 4) and neutrophils could also contribute to both glycosaminoglycan neutralization and serpin inactivation (elastase). Overall, our results suggest that some of the procoagulant state induced by inflammation is due, in part, to the ability of neutrophil lactoferrin to neutralize glycosaminoglycan-catalyzed serpin-thrombin inhibition reactions. aSSays. 42.4h,41 These results suggest that lactofemn, as a spe-
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